Maintenance fees coming due
Cancer Research Technology Limited
32 maintenance fees come due in the 12 months from Nov 22, 2026, the next on Dec 9, 2026. Unpaid by Jun 9, 2027, that one lapses early.
A maintenance fee does not end a patent on its due date. It falls due at 3.5, 7.5
and 11.5 years from grant, and the patent lapses only if the fee is still unpaid at the end of the
six month grace period that follows.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Fee due | Lapses if unpaid | Expires | Confidence |
|---|---|---|---|---|---|---|---|
| US 9,050,321 | Rationally-Designed Anit-avBeta6 Integrin Antibody MFEVP1 and Variants Thereof, Method of Making Such Antibody and the Use Thereof in Treating and Diagnosis of_Disease In force Fee due Dec 9, 2026 Lapses if unpaid Jun 9, 2027 · High confidence | Cancer Research Technology Limited | In force | Dec 9, 2026 | Jun 9, 2027 | High confidence | |
| US 10,323,028 | 1,3,4-Thiadiazole Compounds and Their Use in Treating Cancer In force Fee due Dec 18, 2026 Lapses if unpaid Jun 21, 2027 · High confidence | Cancer Research Technology Limited | In force | Dec 18, 2026 | Jun 21, 2027 | High confidence | |
| US 11,680,068 | Compounds Useful as RET Inhibitors In force Fee due Dec 20, 2026 Lapses if unpaid Jun 21, 2027 · High confidence | Cancer Research Technology Limited | In force | Dec 20, 2026 | Jun 21, 2027 | High confidence | |
| US 11,697,688 | ANTI-CD25 for Tumour Specific Cell Depletion In force Fee due Jan 11, 2027 Lapses if unpaid Jul 12, 2027 · High confidence | Cancer Research Technology Limited and Tusk Therapeutics Ltd. | In force | Jan 11, 2027 | Jul 12, 2027 | High confidence | |
| US 10,399,974 | N2-PHENYL-PYRIDO[3,4- D]PYRIMIDINE-2, 8-Diamine Derivatives and Their Use as MPS1 Inhibitors In force Fee due Mar 3, 2027 Lapses if unpaid Sep 3, 2027 · High confidence | Cancer Research Technology Limited | In force | Mar 3, 2027 | Sep 3, 2027 | High confidence | |
| US 10,400,008 | Modulators of the Src-Kinase Activity for Preventing or Treating Metastatic Cancer In force Fee due Mar 3, 2027 Lapses if unpaid Sep 3, 2027 · High confidence | Cancer Research Technology Limited | In force | Mar 3, 2027 | Sep 3, 2027 | High confidence | |
| US 11,753,405 | 1,3,4-Thiadiazole Compounds and Their Use in Treating Cancer In force Fee due Mar 12, 2027 Lapses if unpaid Sep 13, 2027 · High confidence | AstraZeneca AB and Cancer Research Technology Limited | In force | Mar 12, 2027 | Sep 13, 2027 | High confidence | |
| US 10,414,726 | Therapeutic Agents In force Fee due Mar 17, 2027 Lapses if unpaid Sep 17, 2027 · High confidence | Cancer Research Technology Limited | In force | Mar 17, 2027 | Sep 17, 2027 | High confidence | |
| US 11,766,434 | Pyrimidinone Derivatives as CDC7 Inhibitors In force Fee due Mar 26, 2027 Lapses if unpaid Sep 27, 2027 · High confidence | Cancer Research Technology Limited | In force | Mar 26, 2027 | Sep 27, 2027 | High confidence | |
| US 10,428,061 | Autotaxin Inhibitors In force Fee due Apr 1, 2027 Lapses if unpaid Oct 1, 2027 · High confidence | Cancer Research Technology Limited | In force | Apr 1, 2027 | Oct 1, 2027 | High confidence | |
| 22 more maintenance fees coming due in the 12 months from Nov 22, 2026 · Pro | |||||||
10 of 32 patents shown. Soonest fee due date first, then patent number.
Pro members see every patent with a maintenance fee coming due: number, title, status, the due date, and the date it lapses if the fee goes unpaid through the grace period.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.